Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of erlotinib with or without CP-751,871 in advanced non-adenocarcinoma non-small cell lung cancer
2008-001168-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing CP-751,871 + erlotinib with erlotinib (2 arms). Primary endpoint: Overall survival. Started May 2008; status: completed.
02
Drugs
erlotinibfigitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-001168-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001168-35.